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Abstract: Macrophages interact with cells in every organ to facilitate tissue development, function
and repair. However, the close interaction between macrophages and parenchymal cells can be
subverted in disease, particularly cancer. Motility is an essential capacity for macrophages to be
able to carry out their various roles. In cancers, the macrophage’s interstitial migratory ability
is frequently co-opted by tumor cells to enable escape from the primary tumor and metastatic
spread. Macrophage accumulation within and movement through a tumor is often stimulated by
tumor cell production of the mononuclear phagocytic growth factor, colony-stimulating factor-1
(CSF-1). CSF-1 also regulates macrophage survival, proliferation and differentiation, and its many
effects are transduced by its receptor, the CSF-1R, via phosphotyrosine motif-activated signals.
Mutational analysis of CSF-1R signaling indicates that the major mediators of CSF-1-induced motility
are phosphatidyl-inositol-3 kinase (PI3K) and one or more Src family kinase (SFK), which activate
signals to adhesion, actin polymerization, polarization and, ultimately, migration and invasion in
macrophages. The macrophage transcriptome, including that of the motility machinery, is very
complex and highly responsive to the environment, with selective expression of proteins and splice
variants rarely found in other cell types. Thus, their unique motility machinery can be specifically
targeted to block macrophage migration, and thereby, inhibit tumor invasion and metastasis.
Keywords: macrophage motility; colony-stimulating factor-1; phosphatidyl-inositol-3-kinase;
Src family kinases; paracrine interaction.
1. Introduction
Macrophages are found throughout the body where they contribute to tissue development,
remodeling and homeostasis [1]. These multifunctional cells can be considered accessory or
housekeeping cells, as they support the diverse needs of parenchymal cells in different tissues [2].
Hence, resident macrophages survey the local environment, secrete trophic factors, phagocytose cells
and debri, and carry out repairs to maintain homeostasis. Their distribution within each tissue is
also highly structured to enable functional coordination within the neighborhood and their trophic
and repair capacities are tightly regulated to ensure activation occurs only when appropriate [2].
To integrate seamlessly into different tissue environments and carry out tissue-specific functions, as
well as general housekeeping functions, macrophages undergo a remarkable degree of transcriptional
reprogramming in response to local cues [3]. This plasticity can be problematic when regulatory
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mechanisms fail in different disease states, as their developmental functions can be reactivated and
their housekeeping functions subverted, to promote disease progression in conditions ranging from
atherosclerosis and arthritis, to cancer [4,5].
Despite their functional complexity, macrophages are frequently categorized in a binary manner
as either classically activated, pro-inflammatory (M1) or alternatively activated, anti-inflammatory
(M2) macrophages, following exposure to interferon-γ (IFN-γ) and bacterial infections or interleukin
(IL)-4 and IL-13, and parasitic infections, respectively (Figure 1) [6].
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within a single tissue and, particularly in pathological conditions where the microenvironment can 
be highly variable such as in tumors, macrophages may develop mixed phenotypes [5]. Solid tumors 
frequently contain large numbers of tumor-associated macrophages (TAMs), which contribute to 
their development and progression [5,9]. Indeed, a tumor can be thought of as an organ with its own 
integral resident macrophages, which have been groomed by the tumor cells to provide them with 
trophic factors for growth and vascular supply, as well as aiding them to resist immune attack and 
cancer therapies [5,9]. 
Interstitial migration is central to the macrophage function as they patrol tissues to carry out 
their many developmental and housekeeping duties [10]. Live imaging of mouse mammary tissue 
showed macrophages crawling along and between collagen fibers at rates of approximately 5 µm/min 
[11]. Colony-stimulating factor-1 (CSF-1), the macrophage growth factor, was originally 
demonstrated to signal to survival, proliferation and differentiation of cells of the mononuclear 
phagocytic (MNP) lineage, including monocytes and macrophages [12]. It is found at biologically 
active concentrations throughout the body and, importantly, is considered the primary cytokine in 
macrophage development [12]. Consequently, an international collective of macrophage biologists 
determined that macrophages grown in CSF-1 should be labeled baseline (M0) macrophages that 
subsequently may be activated by other factors in the microenvironment, such as IFN-γ or IL-4 
(Figure 1) [13]. Hence, CSF-1 is considered a maturation rather than an activation factor. Consistent 
with this, CSF-1 stimulates differentiation of mouse and human monocytes into mature, adherent 
macrophages after which it remains an important survival factor [10,13,14]. CSF-1 is also a critical 
regulator of macrophage motility, i.e., it is a macrophage chemokine [15–18]. Considering the 
Figure 1. Colony-stimulating factor-1 (CSF-1) induces macrophage precursors to mature into adherent,
motile baseline macrophages (M0). M0 macrophages are then activated into pro-inflammatory
macrophages by IFNγ and LPS or anti-inflammatory, pro-tumoral macrophages by IL-4 or IL-13.
Definitions: LPS, lipopolysaccharide; IFNγ, interferon-γ; IL, interleukin.
As M2 activation can also be caused by other stimuli, M2 macrophages have been further stratified
in terms of homeostasis, host defense, wound repair and immune regulation [7], although recent results
indicate that activation phenotypes are far more complex than that which can be accommodated by a
linear continuum [3,8]. Moreover, different macrophage populations co-exist within a single tissue
and, particularly in pathological conditions where the microenvironment can be highly variable such
as in tumors, macrophages may develop mixed phenotypes [5]. Solid tumors frequently contain
large numbers of tumor-associated macrophages (TAMs), which contribute to their development
and progression [5,9]. Indeed, a tumor can be thought of as an organ with its own integral resident
macrophages, which have been groomed by the tumor cells to provide them with trophic factors for
growth and vascular supply, as well as aiding them to resist immune attack and cancer therapies [5,9].
Interstitial migration is central to the macrophage function as they patrol tissues to carry
out their many developmental and housekeeping duties [10]. Live imaging of mouse mammary
tissue showed macrophages crawling along and between collagen fibers at rates of approximately
5 µm/min [11]. Colony-stimulating factor-1 (CSF-1), the macrophage growth factor, was originally
demonstrated to signal to survival, proliferation and differentiation of cells of the mononuclear
phagocytic (MNP) lineage, including monocytes and macrophages [12]. It is found at biologically
active concentrations throughout the body and, importantly, is considered the primary cytokine in
macrophage development [12]. Consequently, an international collective of macrophage biologists
determined that macrophages grown in CSF-1 should be labeled baseline (M0) macrophages that
subsequently may be activated by other factors in the microenvironment, such as IFN-γ or IL-4
(Figure 1) [13]. Hence, CSF-1 is considered a maturation rather than an activation factor. Consistent
with this, CSF-1 stimulates differentiation of mouse and human monocytes into mature, adherent
macrophages after which it remains an important survival factor [10,13,14]. CSF-1 is also a critical
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regulator of macrophage motility, i.e., it is a macrophage chemokine [15–18]. Considering the
importance of interstitial migration for macrophages in both health and disease, regulation of this
process by CSF-1 deserves more attention. This review focuses on motility signals transduced by
the CSF-1R upon activation by CSF-1, and how these signals might be targeted to treat disease,
particularly cancer.
2. Macrophage Motility and CSF-1/CSF-1R Axis in Development and Homeostasis
Studies of organisms deficient in CSF-1 or its receptor have revealed the importance of
macrophages in matrix remodeling, branching morphogenesis and phagocytosis of dying cells during
organogenesis [11,19–24]. Consistent with the central role of CSF-1 in the regulation of motility, a loss
of function in CSF-1R mutation in zebrafish specifically stops primitive yolk sac-derived macrophages
from migrating into embryonic tissues [25]. The microglial population is particularly affected by
this migratory defect. Similarly, inactivation of Csf1 in the osteopetrotic mouse (Csf1op/op) produces
multiple congenital abnormalities, many of which may result from failure of primitive macrophages
to migrate into and populate developing tissues [23,26,27]. Notably, CSF-1 is secreted by mammary
epithelial cells to recruit macrophages into the developing mouse mammary gland, where they migrate
along and remodel collagen fibrils to enable terminal end bud lengthening [11]. Motility may also be
required for their role in branching morphogenesis and vascular anastomosis [15]. Recently, mutations
in the human CSF-1R have been shown to underpin an autosomal dominant form of early onset
dementia, hereditary diffuse leukoencephalopathy with spheroids (HDLS), which predominantly
affects frontal lobe white matter [28,29]. Interestingly, the CSF-1R mutations all occur in the kinase
domain and lead to reduced expression and phosphorylation of the receptor, indicating that CSF-1R
haploinsufficiency is sufficient to cause HDLS, which is also known as adult-onset leukodystrophy,
with axonal spheroids and pigmented glia (ALSP) [30,31]. Importantly, primitive macrophage-derived
microglia are CSF-1 dependent, and both their morphology and distribution in the frontal lobe
white matter are aberrant in patients with HDLS, suggesting microglial motility may play a role
in the pathogenesis of this condition [30,32]. The neurologically restricted phenotype of HDLS,
which is consistent with neuro-developmental findings in a Csf1r+/− mouse model, suggests that
microglial CSF-1R signaling is particularly critical for normal cortical white matter development
and maintenance [31]. Finally, the central role of migratory macrophages in the patterning of adult
zebrafish stripes has recently been demonstrated [33,34], which leads to the aberrant pigmentation of
Csf1r mutant zebrafish [25].
In the adult organism, resident macrophages contribute to the homeostasis of their tissues of
residence through immune surveillance and wound healing as well as through trophic and phagocytic
activity. Macrophages may form up to 20% of tissue mass in organs such as the liver [20,35] and,
as mentioned earlier, they form complex networks within the tissues to efficiently patrol and clean
the neighborhood. Macrophages play a pivotal role in metabolic homeostasis and energy regulation
through their integration in the liver, pancreatic islets and adipose tissue, while in the spleen, they
phagocytose senescent erythrocytes and recycle essential components such as iron, and microglia
are important for learning and memory [2,36–38]. Hence, different populations of macrophages
have essential developmental and homeostatic functions in all tissues, helping parenchymal cells
to function normally and respond appropriately to variable demands. CSF-1 is important for the
maintenance of most, if not all, of these populations, although additional cytokines also regulate
macrophage development and behavior. The most notable of these is IL-34, which was discovered
following the demonstration that the Csf1r−/− mouse was more severely affected than the Csf1−/−
mouse [39,40]. CSF-1 is the dominant cytokine of the two as the main effects of IL-34 are in the
development of Langerhans cells in the skin and some microglial populations and the IL-34−/−
mouse is essentially normal [41–43]. Macrophage proliferation can also be stimulated by granulocyte
macrophage (GM)-CSF or IL-4 [44,45] but macrophages grown in GM-CSF are less adherent and
elongated while IL-4-activated macrophages elongate and move faster than those grown in CSF-1
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alone [44,46–48]. Nevertheless, CSF-1 is considered to be the fundamental growth factor regulating
production and differentiation of mature macrophages with an adherent and motile M0 phenotype [13].
3. Macrophage Motility and CSF-1 in Cancer
Due to their functional integration in tissues and organ systems, macrophages are readily
subverted by disease mechanisms in those same tissues [49]. They contribute to the development
and progression of atherosclerotic plaques [50], obesity and metabolic disease [38], rheumatoid
arthritis [51], and neurological disorders such as multiple sclerosis [52]. The most striking pathological
involvement of macrophages is their largely deleterious role in the progression of cancer to invasion
and metastasis [5,9,12,53]. TAMs are principally derived from circulating monocytes rather than from
proliferation of local tissue-resident macrophages [54], and they contribute to a number of cancer
hallmarks, including stimulation of tumor cell proliferation and angiogenesis through production
of growth factors (Figure 2) [9,12]. However, perhaps the most lethal aspect of their role in cancer
progression is their promotion of tumor invasion and metastasis [55]. Macrophage-deficient female
CSF-1-deficient mice, when crossed with the mammary tumor-prone Polyoma middle T antigen (PyMT)
mouse, rarely develop pulmonary metastases, despite the formation of large numbers of primary
mammary epithelial tumors [56]. As mentioned above, CSF-1 is secreted by ductal epithelial cells to
recruit macrophages, which are required for normal mammary gland development and homeostasis [7],
but it is also secreted by breast cancer cells to recruit TAMs, which promote progression of the cancer
to invasion and metastasis [57]. A paracrine interaction between CSF-1-secreting tumor cells and
epidermal growth factor (EGF)-secreting TAMs stimulates relay chemotaxis through direct cell-cell
contact, leading to invasion of both cell types together towards blood vessels (Figure 2) [5,57–59].
Indeed, streams of TAMs and tumor cells have been seen migrating together along collagen fibers
within tumors [60]. Accordingly, high TAM densities correlate strongly with metastatic breast cancer,
and high CSF-1 levels coincide with dense TAM foci at invading fronts of breast cancers [55,61–63].
High TAM counts are associated with a poor prognosis in a number of cancers, including cervical
cancer, endometrial cancer, prostate cancer, lung cancer, pancreatic cancer and glioblastoma [64–69].
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Figure 2. Contribution by tumor-associated macrophages (TAM) to tumor progression with an
emphasis on tumor invasion and metastasis. TAMs secrete epidermal growth factor (EGF) and tumour
cells secrete CSF-1 to induce a paracrine loop-driven co-migration and invasion of both cell types
towards blood vessels.
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Consistent with the role of CSF-1-dependent, TAM-activated tumor invasion, high CSF-1 levels
are also associated with poor prognoses in many cancers, leading to the testing of a variety of
anti-CSF-1/CSF-1R therapies to either reduce or reprogram TAMs to treat cancer [70]. Indeed, patients
with a rare synovial cell-derived diffuse-type giant cell tumor, which results from a translocation
event that causes uncontrolled CSF-1 production by synovial cells with consequent recruitment of
huge numbers of macrophages, responded dramatically to administration of an antibody blocking the
CSF-1R (emactuzumab) [71]. Furthermore, anti-CSF-1/CSF-1R therapies have produced encouraging
therapeutic responses in pre-clinical tumour models, particularly in combination with chemotherapy
or radiotherapy [72–74], or when used to reprogram tumor-promoting TAMs into anti-tumoral
TAMs [69,75]. Hence, a number of clinical trials with small molecule inhibitors or antibodies targeting
the CSF-1R are currently underway [9]. However, there is some evidence that CSF-1R blockade may
encourage accumulation of deleterious tumor-associated neutrophils [76]. This may be due to the
effect of CSF-1R inhibition on anti-tumoral macrophage populations as functionally distinct TAM
populations are found within tumours [77]. Therefore, since the metastatic spread of tumors accounts
for the vast majority of cancer deaths and TAMs activate tumor invasion and metastasis through
paracrine CSF-1/EGF signalling (Figure 2), inhibition of specific CSF-1R signals supporting pro-tumoral
TAM behaviour may leave anti-tumoral TAM populations relatively unaffected. Hence, development
of therapies targeting TAM motility may be an effective approach to prevent the co-migration and
invasion of tumor cells with TAMs.
4. Regulation of Macrophage Motility by CSF-1R Signaling
CSF-1 supports survival, proliferation, differentiation and migration in macrophages and the
mononuclear phagocytic progenitor cells from which they are derived. Reflecting the chameleon-like
ability of differentiating macrophages to adapt to their different tissues of residence, their transcriptome
is both highly complex and extremely plastic [3]. Nevertheless, whatever their final tissue of residence,
CSF-1 induces their maturation from circulating monocytes into adherent and motile tissue-resident
macrophages [10]. Consistent with this notion, CSF-1 induces the expression of adhesion and motility
molecules [44,78,79], and stimulates tyrosine phosphorylation of significantly more cellular proteins
than does GM-CSF [80].
Like other receptor tyrosine kinases (RTKs), the CSF-1R transduces CSF-1’s effects via a series of
tyrosine phosphorylation events (Figure 3) [18,46]. Upon CSF-1 binding, the receptor phosphorylates
up to 8 intracellular tyrosine residues and the resulting phosphotyrosine motifs create specific
docking sites for phosphotyrosine (pTyr) binding domain-containing proteins. Docked molecules
trigger multiple downstream signals to produce and maintain macrophage numbers and functional
capacities [18,46]. To tease apart individual pathways mediating the pleiotropic effects of CSF-1,
we developed a macrophage cell line system with individual tyrosine-to-phenylalanine mutant
CSF-1Rs expressed in macrophages derived from the CSF-1R−/− mouse [44]. The system was used
to demonstrate that specific CSF-1R pTyr motifs regulate macrophage morphology, while others are
critical for macrophage proliferation and differentiation [44,81]. Two pTyr residues in particular were
subsequently shown to regulate macrophage motility, pY721 in the kinase insert domain and pY974 at
the C-terminus (Figure 3) [14,79].
Interestingly, the pathways activated by the two pTyr motifs are quite different and shed light
on the mechanisms by which CSF-1R signaling regulates motility in macrophages acutely through
rapid stimulation of cell ruffling, membrane protrusion and adhesion and in the longer term through
stimulation of gene transcription (Figure 3) [10].
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Figure 3. Schematic of the colony-stimulating factor-1 receptor (CSF-1R) and downstream motility
signaling. Upon binding of CSF-1, the CSF-1R homo-dimerizes and autophosph rylates up to eight
tyrosine residues. Both the pY72 and pY974 m tifs have been shown to be import nt for motility
signaling. pY721 directly stimulates macrophage motility through activation of PI3K p110δ, leading to
activation of downstream signalling involving the Rho GTPases (Rac, Rho and Cdc42), Akt and PDK1.
pY974, which has been de onstrated to bind the E3 ubiquitin ligase, c-Cbl, also indirectly affects
motility signalling through regulation of expression of Src family kinases (SFK). Hck, and possibly
other SFKs, directly regulate CSF-1-induced motility, likely through integrin-mediated activation of
adhesion and actin polymerization.
5. CSF-1R pY721, PI3K Signaling and Macrophage Motility
In macrophages deprived of CSF-1, rapid activation of actin polymerization underpins the dorsal
ruffling that becomes visible within a minute of CSF-1 addition [79]. This is swiftly followed by
cell spreadi as lamellipodia ext nd circumferentially, supported by the formation of countless
dot-like adhesions on the ventr l surface of the c ll [10,82,83]. Maximal spreading occurs wi hin
approximately five minutes [84], after which macrophages polarize, elongate and move pe istently
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towards the source of CSF-1 [16,85]. Y721F mutant CSF-1R-expressing macrophages are deficient in all
the CSF-1-stimulated steps leading to motility outlined above, namely, ruffling and spreading, adhesion
formation and elongation, resulting in a striking reduction in their motility in vitro and in vivo [79].
Critically, there is also a significant reduction in their capacity to enhance tumor cell invasion in vitro
and in vivo [79]. The CSF-1R Y721 motif, when phosphorylated, associates with, and activates,
phosphatidylinositol 3-kinase (PI3K), which rapidly produces a pulse of PI 3,4,5-trisphosphate (PIP3)
at the cell membrane [79,86,87]. Thus, like other RTKs, the CSF-1R activates class IA PI3Ks via direct
association of their p85 regulatory subunit with the preferred pYXXM motif in the RTK which, in the
case of CSF-1R Y721, is pYVEM in the kinase insert region (Figure 3). p85 PI3K may also associate
indirectly with the receptor either through its association with SFKs at CSF-1R pY559 or with c-Cbl at
CSF-1R pY974, but this indirect association is at very low levels and occurs significantly later than the
pY721-based association [46,79,87,88].
Class 1A PI3Ks consist of three p110 catalytic isoforms constitutively associated with the
regulatory p85 subunit. Macrophages express all three of them; the ubiquitously expressed p110α and
p110β isoforms, and the hematopoietically expressed p110δ, and they have non-redundant biological
roles [84,89,90]. Together, their activation triggers a plethora of signals to growth, survival, proliferation
and migration by inducing the translocation of pleckstrin homology (PH) domain-containing molecules
such as Akt/PKB [91,92]. Use of selective inhibitors for each of the three class 1A p110 isoforms
has clearly shown that p110δ is the specific isoform triggering CSF-1-induced macrophage motility
and invasion [84,89]. p110δ-produced PIP3 activates signaling pathways that are yet to be fully
elucidated, but which stimulate two waves of actin polymerization within 5 minutes and a slightly later
increase in paxillin phosphorylation to underpin the CSF-1-induced ruffling, spreading and adhesion
formation [79,84]. Two PI3K-activated pathways known to influence cell motility are PDK1/Akt and
Rac signaling (Figure 3). Although CSF-1-induced Akt phosphorylation is reduced and its kinetics
slowed in CSF-1R Y721F macrophages, significant Akt phosphorylation still occurs in these cells in the
absence of any PIP3 production [79,84]. This partial uncoupling of motility and Akt activation suggests
Akt-independent pathways also regulate pY721-stimulated motility. Likely candidates include PDK1,
the S/T kinase responsible for activating Akt but which also activates several isoforms of PKC that
may control cell motility [93]. Similarly, CSF-1-based regulation of PH domain-containing guanine
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) may also play a role
through modulation of the activities of their target Rho family GTPases, Rho, Rac and Cdc42 [10,79].
Rho family GTPases are well known regulators of actin polymerization and cell adhesion downstream
of RTKs in many different cell types through their interaction with a variety of effector proteins [94].
Selective expression of individual Rho family GTPase members and their GEFs, GAPs and effector
proteins results in highly complex and dynamic coordination of cytoskeletal remodeling in response
to RTK stimulation [10,94]. A wide range of approaches in CSF-1-dependent macrophage cell lines,
from microinjection of Rho family GTPases to fluorescence resonance energy transfer (FRET), have
been used to determine the specific roles played by individual Rho family GTPases in macrophage
motility. Cdc42 is important for sensing of CSF-1 gradients, membrane protrusions, especially filopodia
and focal complex formation [85,95,96]. CSF-1-induced activation of Rac stimulates ruffling and
lamellipodial spreading plus adhesion while Rho triggers retraction of the trailing edge via actomyosin
contractility in bone marrow-derived macrophages (BMM) [83,84,97,98]. While the complexities and
redundancies of Rho family GTPase signaling make it difficult to further tease apart their specific roles
in CSF-1-induced motility or determine their upstream activators, it is apparent that PI3K activation is
central to their mediation of CSF-1-induced macrophage motility. Hence, macrophage motility is more
likely to be successfully targeted by inhibiting PI3K-induced PIP3 production at the top of the radiating
motility signaling network in macrophages. Furthermore, p110δ is the specific PI3K isoform producing
PIP3 in response to CSF-1 stimulation in macrophages and a selective p110δ inhibitor, idelalisib, is
already used in the clinic to treat patients with neoplastic B cell disorders such as chronic lymphocytic
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leukemia [99]. Widening the clinical applications of idelalisib to inhibition of solid tumor invasion by
preventing migration and invasion of TAMs in these tumors, may prove clinically useful.
6. CSF-1R pY974, SFKs and Macrophage Motility
The SFKs have many roles in many different cell types. However, a key function of this family of
non-receptor tyrosine kinases is the regulation of cell adhesion and motility [100,101]. Macrophages
express six of the eight mammalian SFKs at some stage in their maturation process, reflecting the
complex and plastic proteome of these cells. Three of the six, Src, Fyn and Yes, are broadly expressed
in most cell types, but the remaining three, Hck, Fgr and Lyn, are primarily myeloid SFKs [102].
In keeping with the role of SFKs in adhesion and motility, CSF-1-induced maturation of macrophages
from non-adherent precursor cells into adherent, migratory macrophages, produces marked changes
in the expression of Src, Fyn and Fgr [14]. While there are specific biological effects for each of the
SFKs expressed in macrophages, overlapping effects are common [103]. This was made abundantly
clear when the sole phenotype of the Src-deficient mouse was osteopetrosis, due to loss of osteoclast
resorptive capacity, and deficiency of both Yes and Fyn, as well as Src, were needed to produce
embryonic lethality [104,105]. Indeed, the expression levels of individual SFKs may be coupled with
those of other SFKs. For example, a striking reduction in Src levels is associated with increased Hck
and Fgr expression in macrophages expressing a CSF-1R with a mutation in the C-terminal tyrosine
(Y974F) and these macrophages have reduced motility (Figure 3) [14]. Accordingly, pan-SFK targeting
inhibits CSF-1-stimulated motility and invasion in macrophages [14]. Moreover, SFK inhibition
completely blocks co-migration and invasion of co-cultured macrophages and tumor cells into Matrigel
in an in vitro invasion model [106]. To specifically target macrophage motility in this co-invasive
behavior, it is important to identify which macrophage SFKs mediate the CSF-1 signal to motility and
invasion. Similar to the ubiquitous SFKs, mice lacking myeloid SFKs, either individual or in dual
combinations, did not show any defects in macrophage motility in a thioglycollate-induced peritonitis
model and loss of all three myeloid SFKs was needed to uncover a motility phenotype in vivo [103,107].
In vitro studies of motility in BMM extracted from the various myeloid SFK mutant mice examined
G-protein coupled receptor-mediated chemokine responses and integrin-based signaling but not
CSF-1-induced motility [103]. Nevertheless, integrin-based studies revealed that both Hck and Fgr
mediate macrophage adhesion signaling through α5β1 integrin during spreading on fibronectin and
macrophages lacking both SFKs have reduced motility [108]. The two SFKs are redundant as the
single mutant BMM counterparts do not display apparent adhesion and motility deficiencies [108].
Unsurprisingly, spreading and motility defects are more profound when all three myeloid SFKs
are lost [107]. However, compensatory changes in expression of the remaining ubiquitous and
myeloid SFKs in macrophages following knockout of one or more SFKs will likely confound these
results and approaches to either acutely reduce the expression of individual SFKs or, alternatively,
to activate specific SFKs through mutation of the negative regulatory C-terminal tyrosine or use of
inducible, activatable constructs will help tease apart specific functions for individual SFKs [109].
Our understanding of which SFKs mediate CSF-1R signaling to motility in macrophages is still
somewhat rudimentary but, as a group, they are key transducers of CSF-1R signaling through
augmentation of phosphotyrosine-based signaling [18,46]. Both Hck and Lyn associate with the
CSF-1R, Hck in a CSF-1 dependent manner and Lyn constitutively, with a notable CSF-1-induced
increase in Hck tyrosine phosphorylation [14]. Consistent with this, we have examined BMM extracted
from mice with a constitutive activation mutation of the Hck gene [110], and found that they move
more rapidly than wild type BMM in response to CSF-1 and degrade and invade matrix significantly
more efficiently than controls [111]. Considering expression levels of the other macrophage SFKs
are unaltered in these Hck mutant BMM, it would appear that Hck is a major, if not the primary,
SFK transducing the CSF-1R motility signal in macrophages. Importantly, a Hck selective inhibitor,
RK-20449, has recently been developed and has been shown to promote tumor regression in mouse
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xenograft models [112,113]. Hence, inhibition of macrophage motility by targeting Hck with RK-20449
may be a viable therapeutic approach.
7. Inhibiting CSF-1-induced Macrophage Motility to Prevent Tumor Invasion
TAMs contribute to the development and progression of cancer at almost every step in the
complex process [114]. Moreover, chemotherapy and radiotherapy appear to further encourage
TAM recruitment with negative consequences for treatment response [115]. In particular, TAMs
play a critical role in encouraging tumor invasion through induction of a paracrine dialog between
tumor cells and closely associated TAMs, which leads to their co-migration and invasion away
from the primary tumor [56,58,59]. Consistent with this, 3D studies of mammary tumor spheroid
invasion demonstrate that tumor cells are incapable of invasion into the surrounding matrix unless the
spheroids are infiltrated with macrophages, indicating that macrophages trigger and support tumor
cell invasiveness [106,116]. Live imaging of the tumor cells and macrophages highlights the streams of
co-migrating macrophages and tumor cells as they invade the Matrigel and macrophages can be seen
encouraging tumor cell migration as they follow macrophages through tunnels previously dug by those
macrophages [106]. Consistent with the notion that macrophage motility regulates tumor invasion
rates, hyper-motile macrophages provoke greater tumor invasion [111], while selective inhibition of
macrophage motility with idelalisib or RK-20449 completely blocks tumor invasion in this co-culture
spheroid model [106]. With the identification of two core CSF-1R-triggered motility pathways involving
PI3K p110δ and Hck that are selectively expressed in hematopoietic cells and abundantly expressed in
macrophages, we can now specifically target migratory macrophages to prevent their promotion of
tumor invasion without depleting tumors of more stationary TAM populations that may be providing
anti-tumoral functions.
8. Concluding Remarks
Macrophages and other mononuclear phagocyte-derived cells, such as osteoclasts and microglia,
integrate with parenchymal cells in every tissue and organ system during early embryogenesis.
As they move through tissues, they monitor their local environment and respond to perturbations in
the steady state. Tumors are aberrant tissues populated with their own population of tissue-adapted
macrophages, TAMs. As CSF-1 is the primary regulator of most tissue macrophage populations,
including TAMs, and is also a potent macrophage chemokine, CSF-1 or CSF-1R inhibitors have been
tested clinically to determine whether they could successfully block TAM recruitment. However, full
CSF-1R blockade may have deleterious effects by also inhibiting and depleting anti-tumoral TAM
populations. Hence, selective targeting of specific functions of tumor-promoting macrophages, such as
their promotion of tumor cell invasion through co-migration of TAMs and tumor cells, might prove to
be more therapeutically useful. Using a series of CSF-1-dependent, adherent macrophage cell lines
expressing CSF-1R molecules with mutations in individual tyrosine residues, the primary mediators of
CSF-1-induced signals regulating macrophage motility and invasive capacity were demonstrated to be
a Class 1A PI3K, PI3K p110δ, and a myeloid SFK, Hck. Isoform selective PI3K p110δ and Hck inhibitors
are available and may be deployed to prevent the activation of tumor invasion by co-migrating TAMs,
which not only provide EGF to stimulate tumor cell motility, but also dig tunnels into the surrounding
matrix through which tumor cells can escape.
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